CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
97.26
+0.11 (+0.11%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close97.15
Open97.14
Bid97.27 x 900
Ask97.27 x 1800
Day's Range96.79 - 97.46
52 Week Range58.59 - 97.89
Volume639,717
Avg. Volume6,786,395
Market Cap68.594B
Beta (3Y Monthly)1.82
PE Ratio (TTM)14.81
EPS (TTM)6.57
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est97.00
Trade prices are not sourced from all markets
  • Big Drugmakers That May Tread the M&A Path After Pfizer
    Zacks2 hours ago

    Big Drugmakers That May Tread the M&A Path After Pfizer

    There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

  • Celgene (CELG) Hits 52-Week High, Can the Run Continue?
    Zacksyesterday

    Celgene (CELG) Hits 52-Week High, Can the Run Continue?

    Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • 4 High Earnings Yield Stocks to Strengthen Your Portfolio
    Zacksyesterday

    4 High Earnings Yield Stocks to Strengthen Your Portfolio

    Earnings yield is very effective for determining undervalued stocks.

  • Markityesterday

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELGView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CELG had net inflows of $1.76 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzingayesterday

    The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...

  • Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
    Zacks2 days ago

    Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

    Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

  • Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
    Zacks2 days ago

    Regeneron (REGN) Presents Positive Data on Lymphoma Candidate

    Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.

  • Is It Too Late to Buy Celgene Stock?
    Motley Fool3 days ago

    Is It Too Late to Buy Celgene Stock?

    The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?

  • Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
    PR Newswire5 days ago

    Leoplus USA Wins Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"

    Leoplus USA is developing Duet, a device and app which aims to support communications between people with MS and their care partners to help improve patients' disease management outcomes. "We know communication within families affected by multiple sclerosis can be challenging. Duet is an innovative way to create connections with those you love," said Tim Coetzee, Ph.D., Chief Advocacy, Services and Research Officer at the National Multiple Sclerosis Society, who served as chair of the judging panel.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...

  • Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
    Zacks5 days ago

    Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

    Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

  • Celgene (CELG) Stock Sinks As Market Gains: What You Should Know
    Zacks6 days ago

    Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Celgene (CELG) closed at $96.36, marking a -0.21% move from the previous day.

  • Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
    Zacks7 days ago

    Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop

    Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks7 days ago

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Boost Your Portfolio's Health With These 3 Big Drug Stocks
    Zacks7 days ago

    Boost Your Portfolio's Health With These 3 Big Drug Stocks

    The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

  • 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
    Motley Fool7 days ago

    5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

    New blockbusters could be on the way for five drugmakers.

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zacks8 days ago

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene
    Zacks8 days ago

    Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene

    Zacks.com featured highlights include: Arconic, Amdocs, Tyson Foods, Target and Celgene

  • Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
    InvestorPlace8 days ago

    Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

    Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.Source: Zynerba PharmaceuticalsThe stock was up 8% in pre-market trading and there's potential for this name to run even further once investors catch wind of it. We're seeing that play out now, with shares up 18% in Tuesday morning trading.With a market capitalization just under $250 million, it's not a well-known player like Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG). In the same light, it's not even a well-known cannabis stock, like Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB).InvestorPlace - Stock Market News, Stock Advice & Trading TipsZynerba was issued U.S. Patent No. 10,314,792, which is titled, "Treatment of Autism Spectrum Disorder with Cannabidiol" and runs through 2038. So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The PatentZynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. I say "potential" because there's still a lot of work and progress needed before this becomes a staple in the medicine cabinet, so to say. * 7 Dark Horse Stocks Winning the Race in 2019 The patented treatment "includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol." It was granted during the enrollment period of a Phase 2 BRIGHT study, which is intended to evaluate "the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder."Will it work? At this stage it's impossible to say, but there is promise. GW Pharmaceuticals (NASDAQ:GWPH) has successfully gained traction -- even here in the U.S. -- with its cannabidiol treatment for epileptic seizures. So if Zynerba can show similar successes with its treatment, it may open the door to other possible treatments in the future using its Zygel product. Trading ZYNE Stock Click to Enlarge The big boost in ZYNE stock comes as little surprise. After all, it's got all the right buzzwords working in its favor, even if the company has good intentions. Wall Street latches to these trends and investors aren't afraid to jump on board if they think there's opportunity. That's even as Phase-2 testing has yet to begin.ZYNE stock chart is one of only a few that could make a double-digit gain look fairly modest. Above you can see how it moved over downtrend resistance (blue line) on Monday. Now it's pushing through $13, as well as the 20-day moving average.Can this thing ignite through $14 and tag its 2019 high near $16.50? Yes, it can. There's no guarantee that it will, but these sort of momentum boosters can give a huge shot in the arm to small-cap stocks.Whether that justifies a move this powerful, ZYNE stock investors certainly have a reason to be excited. But there's a lot of room on the upside before Zynerba stock exhausts itself.On the downside, I want to see $11 to $11.50 hold as support.This marks the 50-day moving average (which is trending higher) as well as the 38.2% retracement. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday's gains. Bottom Line on ZYNE StockNorth of $13 and the 20-day would be best, but let's see how it trades throughout the day and the rest of this week.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.

  • CELG or VRTX: Which Is the Better Value Stock Right Now?
    Zacks8 days ago

    CELG or VRTX: Which Is the Better Value Stock Right Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
    Zacks8 days ago

    Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

    Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

  • Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate
    Zacks8 days ago

    Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Insider Monkey8 days ago

    Hudson Bay Capital Management’s Return, AUM, and Holdings (Part II)

    Read the beginning of this article here. At the end of the first quarter of 2019, Hudson Bay Capital Management held the most valuable stake in Liberty Expedia Holdings, Inc. (NASDAQ:LEXEA), an online travel company. The fund held 2.04 million Liberty Expedia’s shares with a value of $87.16 million, comprising only 1.14% of its diversified […]

  • 5 Solid Stocks Near 52-Week High Promise to Touch Peak Point
    Zacks9 days ago

    5 Solid Stocks Near 52-Week High Promise to Touch Peak Point

    Investors target stocks that are on a bullish run of late. Stocks witnessing price strength show a high chance of carrying the winning momentum forward.